Clinical Trials Browser

Phase 2 × Has results × lorlatinib × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung